Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women

June 25, 2026 updated by: Nutraland USA, Inc.

A Randomized, Double-Blind, Placebo-Controlled, 6-Week Pilot Study to Evaluate the Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women

The goal of this clinical trial is to learn if ZenRest™ (Lotus Seed & Rice Germ Extract Blend) can help improve sleep quality in menopausal women aged 40-65 with mild-to-moderate sleep complaints.

The main questions it aims to answer are:

  • Does taking ZenRest™ daily improve subjective, participant-reported sleep quality compared to a placebo?
  • Does ZenRest™ improve objective sleep metrics, specifically sleep efficiency, when monitored via an Oura Ring wearable device?
  • Does the extract improve secondary sleep and lifestyle factors, such as insomnia severity, daytime sleepiness, and vitality? Researchers will compare ZenRest™ to a placebo (a look-alike capsule that contains no active ingredients) to see if the botanical blend has a measurable effect on sleep quality.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

ZenRest™ is a proprietary blend of Lotus Seed Extract (Nelumbo nucifera) and Rice Germ Extract (Oryza sativa). This trial evaluates the physiological effects of continuous daily intake (50 mg/day) over a 6-week period, specifically targeting menopausal women with mild-to-moderate sleep complaints. The study utilizes a fully decentralized clinical trial framework. Behavior and physiological metrics are collected remotely utilizing home-based, integrated smart ring wearable tracking methodologies to minimize participant burden. In addition to evaluating subjective sleep indices by measuring changes in the Pittsburgh Sleep Quality Index (PSQI) from baseline to end of study, the protocol investigates continuous objective sleep architecture by assessing daily wearable ring data. This secondary analysis utilizes the Oura Ring platform to evaluate advanced parameters, including sleep efficiency, total sleep time, deep sleep and REM sleep duration, sleep latency, and resting heart rate and heart rate variability dynamics.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94109
        • Alethios, Inc.
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Female, aged 40-65 years at time of enrollment
  • Confirmed menopausal status: (a) natural menopause (≥12 consecutive months of amenorrhea without other clinical cause), or (b) surgical menopause (bilateral oophorectomy with documented date of procedure)
  • Positive onboarding sleep screener: rates sleep quality as "Fairly Bad" or "Very Bad" AND reports sleep difficulty at least once per week in the prior month
  • PSQI global score >5 at T0 baseline assessment (formal eligibility gate)
  • Owns and actively uses an Oura Ring Generation 4 at time of enrollment
  • Demonstrates ≥80% Oura Ring wear compliance in the 30 days prior to enrollment, confirmed via Alethios platform sync at onboarding
  • Willing to wear Oura Ring Generation 4 continuously for 42 nights throughout the study period
  • Willing to maintain stable diet, sleep habits, medications, and supplement use throughout the 42-day study period
  • No planned major disruptions to sleep schedule, shift work, or travel across ≥3 time zones during the study period
  • Access to a smartphone or computer to complete eConsent and digital questionnaires
  • Able to provide informed consent via the Alethios eConsent platform

Exclusion Criteria:

  • Current use of prescription sleep medications (benzodiazepines, non-benzodiazepine hypnotics, doxepin, suvorexant) within 30 days of enrollment
  • Current use of melatonin supplements at doses >1 mg/day within 14 days of enrollment
  • Diagnosis of a clinically significant sleep disorder requiring treatment (obstructive sleep apnea unless adequately treated and stable, restless legs syndrome, narcolepsy)
  • Diagnosis of a major psychiatric disorder currently requiring pharmacological treatment
  • Current use of hormone replacement therapy initiated within 90 days of enrollment, or any planned changes to HRT during the study (stable long-term HRT is acceptable)
  • Regular use of GABAergic, serotonergic, or sedating supplements (valerian, passionflower, ashwagandha, kava) within 14 days of enrollment
  • Shift work or schedule regularly requiring sleep between 06:00 and 22:00
  • Planned travel across 3 or more time zones during the 42-day study period
  • Known allergy to lotus, rice, or related botanicals
  • Active cardiovascular, hepatic, renal, or neurological condition that in the PI's judgment would affect sleep or participant safety
  • Participation in another interventional study within 30 days of enrollment
  • In the opinion of the PI, any condition compromising participant safety or data integrity

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ZenRest™ Group
50 mg proprietary lotus seed and rice germ extract blend capsule, taken once daily, 30-60 minutes before bedtime for 6 weeks (42 days).
Dietary supplement: Lotus Seed & Rice Germ Extract
A proprietary blend of Lotus Seed Extract (Nelumbo nucifera) standardized to contain Neferine >/=2.0% and Isoquercitrin & Hyperoside >/=0.5%, and Rice Germ Extract (Oryza sativa) providing Polyamines >/=0.5% calculated as spermidine. Administered as a 50 mg capsule taken orally once daily, 30-60 minutes before bedtime, for 6 weeks (42 days).
Placebo Comparator: Placebo
An identical look-alike microcrystalline cellulose capsule, taken once daily 30-60 minutes before bedtime for 6 weeks (42 days).
Other: Placebo
An identical, matching inactive look-alike capsule containing microcrystalline cellulose. Administered orally once daily, 30-60 minutes before bedtime, for 6 weeks (42 days).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in Subjective Sleep Quality (PSQI Global Score) at Week 6
Time Frame: Baseline (T0) to Week 6 (T42)
Evaluation of the change in the Pittsburgh Sleep Quality Index (PSQI) global summary score. Scores range from 0 to 21, where higher scores indicate worse sleep quality and a 3-point reduction represents the minimum clinically important difference.
Baseline (T0) to Week 6 (T42)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in Objective Sleep Efficiency (%) via Oura Ring at Week 6
Time Frame: Baseline Week (7-days prior to T0) and final week (T42)
Average weekly percentage of time spent in bed classified as sleep, calculated using nightly passive Oura Ring wearable device metrics comparing the baseline week (mean of 7 days prior to starting study product at T0) against the final week (mean of days 36-42).
Baseline Week (7-days prior to T0) and final week (T42)
Change from Baseline Objective Total Sleep Time at Week 6
Time Frame: Baseline Week (7-days prior to T0) and final week (T42)
Total accumulated sleep duration in minutes per night, calculated using nightly passive Oura Ring wearable device metrics comparing the baseline week (mean of 7 days prior to starting study product at T0) against the final week (mean of days 36-42).
Baseline Week (7-days prior to T0) and final week (T42)
Change from Baseline Objective Sleep Latency at Day 42
Time Frame: Baseline Week (7-days prior to T0) to Final Week (T42)
The time taken to transition from full wakefulness to sleep in minutes, calculated using nightly passive Oura Ring wearable device metrics comparing the baseline week (mean of 7 days prior to starting study product at T0) to the final week (mean of days 36-42).
Baseline Week (7-days prior to T0) to Final Week (T42)
Change from Baseline Objective REM Sleep Duration at Day 42
Time Frame: Baseline week (7-days prior to T0) and final week (T42)
Total duration of Rapid Eye Movement (REM) sleep in minutes per night, calculated using nightly passive Oura Ring wearable device metrics comparing the baseline week (mean of 7 days prior to starting study product at T0) against the final week (mean of days 36-42).
Baseline week (7-days prior to T0) and final week (T42)
Change from Baseline Objective Deep Sleep Duration at Day
Time Frame: Baseline week (7-days prior to T0) and final week (T42)
Total duration of Deep (slow-wave) sleep in minutes per night, calculated using nightly passive Oura Ring wearable device metrics comparing the baseline week (mean of 7 days prior to starting study product at T0) against the final week (mean of days 36-42).
Baseline week (7-days prior to T0) and final week (T42)
Change from Baseline Nocturnal Resting Heart Rate at Day 42
Time Frame: Baseline week (7-days prior to T0) and final week (T42)
Average overnight resting heart rate in beats per minute (bpm), calculated using nightly passive Oura Ring wearable device metrics comparing the baseline week (mean of 7 days prior to starting study product at T0) against the final week (mean of days 36-42).
Baseline week (7-days prior to T0) and final week (T42)
Change from Baseline Nocturnal Heart Rate Variability (HRV) at Day 42
Time Frame: Baseline Week (7-days prior to T0) to Final Week (T42)
Overnight Heart Rate Variability (HRV) in milliseconds (ms), calculated using nightly passive Oura Ring wearable device metrics comparing the baseline week (mean of 7 days prior to starting study product at T0) against the final week (mean of days 36-42).
Baseline Week (7-days prior to T0) to Final Week (T42)
Change from Baseline in Insomnia Severity Index (ISI) Total Score at Week 6
Time Frame: Baseline (T0) to Week 6 (T42)
A 7-item questionnaire assessing the severity and impact of insomnia symptoms. Total scores range from 0 to 28, where higher scores indicate greater insomnia severity. A decrease from baseline represents an improvement.
Baseline (T0) to Week 6 (T42)
Change from Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 6
Time Frame: Baseline (T0) to Week 6 (T42)
An 8-item questionnaire measuring a participant's general level of daytime sleepiness across daily activities. Total scores range from 0 to 24, where higher scores indicate greater excessive daytime sleepiness. A decrease from baseline represents an improvement.
Baseline (T0) to Week 6 (T42)
Change from Baseline in Health-Related Quality of Life (SF-36 Domain Scores) at Week 6
Time Frame: Baseline (T0) to Week 6 (T42)
A 36-item tool measuring health status across 8 distinct domains (including vitality and mental health). Each domain is scored from 0 to 100, where higher scores represent a better quality of life and health status. An increase from baseline indicates an improvement.
Baseline (T0) to Week 6 (T42)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nutraland USA, Inc.

Collaborators

Alethios, Inc.

Investigators

  • Principal Investigator: Dr. Bill Clark, PhD, Natprologix, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

June 25, 2026

First Submitted That Met QC Criteria

June 25, 2026

First Posted (Actual)

July 1, 2026

Study Record Updates

Last Update Posted (Actual)

July 1, 2026

Last Update Submitted That Met QC Criteria

June 25, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NLZR-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Menopause

Clinical Trials on Lotus Seed & Rice Germ Extract

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe